Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SUV39H2 | Q9H5I1 | 6/20 | 0.45 |
| ▸ | TLR9 | Q9NR96 | 4/20 | 0.43 |
| ▸ | TLR7 | Q9NYK1 | 4/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | DHODH | Q02127 | 1/20 | 0.41 |
| ▸ | SCD | O00767 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16212467 | 0.93 | SUV39H2 (0.49) | SUV39H2TLR9TLR7KDM4ENPC1 | |
| SCHEMBL16212069 | 0.92 | SUV39H2 (0.48) | SUV39H2TLR9TLR7KDM4ENPC1 | |
| SCHEMBL16212003 | 0.84 | TLR9 (0.53) | SUV39H2TLR9TLR7PDE10AKDM4E | |
| SCHEMBL16212769 | 0.82 | TLR9 (0.47) | SUV39H2TLR9TLR7PDE10AKDM4E | |
| SCHEMBL20739326 | 0.82 | TLR9 (0.48) | SUV39H2TLR9TLR7PDE10AHDAC1 | |
| Acetic Acid SCHEMBL16212317 | 0.81 | SUV39H2 (0.53) | SUV39H2PDE10AHDAC1KDM4EALDH1A1 | |
| Acetic Acid SCHEMBL16212216 | 0.78 | NPC1 (0.59) | SUV39H2TLR9TLR7KDM4EALDH1A1 | |
| SCHEMBL16212395 | 0.77 | NPC1 (0.58) | SUV39H2TLR9TLR7KDM4EALDH1A1 | |
| SCHEMBL16212402 | 0.77 | TLR9 (0.61) | SUV39H2TLR9PDE10AHDAC1KDM4E | |
| SCHEMBL16212156 | 0.77 | TLR9 (0.49) | SUV39H2TLR9TLR7SMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11358962-B2 | 2-hetaryl imidazol[1,2-a]pyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2022-06-14 | — | — | US | disclosed |
| US-10975073-B2 | Imaging methods using 2-hetaryl imidazol[1,2-a]pyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2021-04-13 | — | — | US | disclosed |
| US-20190048002-A1 | 2-PHENYL OR 2-HETARYL IMIDAZOL[1,2-a]PYRIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2019-02-14 | — | — | US | disclosed |
| US-20190048003-A1 | 2-PHENYL OR 2-HETARYL IMIDAZOL[1,2-a]PYRIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2019-02-14 | — | — | US | disclosed |
| US-10138234-B2 | 2-phenyl or 2-hetaryl imidazol[1,2-a]pyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2018-11-27 | — | — | US | disclosed |
| EP-2991983-B1 | 2-PHENYL OR 2-HETARYL IMIDAZOL[1,2-A]PYRIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2017-03-01 | — | — | EP | disclosed |
| US-20160244441-A1 | 2-PHENYL OR 2-HETARYL IMIDAZOL[1,2-a]PYRIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2016-08-25 | — | — | US | disclosed |
| EP-2991983-A1 | 2-PHENYL OR 2-HETARYL IMIDAZOL[1,2-a]PYRIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2016-03-09 | — | — | EP | disclosed |
| CN-105164125-A | 2-phenyl or 2-heteroaryl imidazo [1, 2-a ] pyridine derivatives | HOFFMANN LA ROCHE | 2015-12-16 | — | — | CN | disclosed |
| WO-2014177458-A1 | 2-PHENYL OR 2-HETARYL IMIDAZOL[1,2-a]PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190048003-A1 | 2-PHENYL OR 2-HETARYL IMIDAZOL[1,2-a]PYRIDINE DERIVATIVES | HTR3D, GDI2, GDI1 | SUV39H2 3723/4885TLR9 4603/4885TLR7 3921/4885 |
| US-10975073-B2 | Imaging methods using 2-hetaryl imidazol[1,2-a]pyridine derivatives | HTR3D, PTGDR2, PTGIR | SUV39H2 3629/4885TLR9 4609/4885TLR7 3768/4885 |
| US-10138234-B2 | 2-phenyl or 2-hetaryl imidazol[1,2-a]pyridine derivatives | CNKSR1, HCAR3, HCAR1 | SUV39H2 3350/4885TLR9 4381/4885TLR7 3295/4885 |
| US-20160244441-A1 | 2-PHENYL OR 2-HETARYL IMIDAZOL[1,2-a]PYRIDINE DERIVATIVES | HTT, HCAR2, HCAR3 | SUV39H2 888/4885TLR9 4543/4885TLR7 4039/4885 |
| US-20190048002-A1 | 2-PHENYL OR 2-HETARYL IMIDAZOL[1,2-a]PYRIDINE DERIVATIVES | HTR3D, GDI2, GDI1 | SUV39H2 3723/4885TLR9 4603/4885TLR7 3921/4885 |
| US-11358962-B2 | 2-hetaryl imidazol[1,2-a]pyridine derivatives | TBXA2R, HRH2, CYP4F3 | SUV39H2 4170/4885TLR9 4726/4885TLR7 3864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.